All peptides were synthesized by NeoMPS (San Diego, CA, USA) at >90% purity. The H2-Db peptide epitope HPV16 E749-57 (RAHYNIVTF; R9F) was used in each study. All vaccines contained a universal T helper peptide PADRE (AKXVAAWTLKAA).
Peptides were formulated in DPX with a proprietary adjuvant as previously described.50 (link) Briefly, peptides and adjuvant were solubilized in appropriate buffer and mixed with 10:1 (w:w) DOPC/cholesterol mixture (Lipoid GmBH, Germany) to form liposomes. The aqueous mixture was lyophilized to a dry cake which was reconstituted with Montanide ISA51 VG (SEPPIC, France) just prior to injection.
Mice were injected subcutaneously on the right flank with 50 µL of DPX. Each dose of DPX contained 10 µg R9F fused to PADRE and 20 µg adjuvant. When multiple treatments were administered, they were given in the same area but avoiding previous sites of injection.
Peptides were formulated in DPX with a proprietary adjuvant as previously described.50 (link) Briefly, peptides and adjuvant were solubilized in appropriate buffer and mixed with 10:1 (w:w) DOPC/cholesterol mixture (Lipoid GmBH, Germany) to form liposomes. The aqueous mixture was lyophilized to a dry cake which was reconstituted with Montanide ISA51 VG (SEPPIC, France) just prior to injection.
Mice were injected subcutaneously on the right flank with 50 µL of DPX. Each dose of DPX contained 10 µg R9F fused to PADRE and 20 µg adjuvant. When multiple treatments were administered, they were given in the same area but avoiding previous sites of injection.